- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00589550
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
Primary
- To determine the maximum tolerated dose and toxicity of PEG-interferon alfa-2b and sorafenib tosylate in patients with unresectable or metastatic clear cell renal cell carcinoma.
Secondary
- To determine the progression-free survival of patients treated with this regimen.
- To evaluate, in a preliminary manner, the response rate and overall survival of patients treated with this regimen.
- To evaluate the activation of interferon-induced transcription factors in immune cell subsets (including regulatory T cells [T regs]) using a novel flow cytometric assay and correlate this information with clinical outcome.
- To measure circulating levels of IFN-γ and IL-5 for determination of Th1/Th2 status and CD4+, CD25+, and FoxP3 cell number (T regs) in peripheral blood.
OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive oral sorafenib tosylate 2-3 times daily on days 15-56 of course 1 and on days 1-56 of all subsequent courses. Courses repeat every 56 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Blood samples are collected at baseline and periodically during study for correlative laboratory studies. Peripheral blood mononuclear cells are analyzed for STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5) and CD4+, CD25+, and FoxP3 regulatory T cells by flow cytometric assays. Samples are also analyzed for the presence of VEGF, VEGFR, IFN-γ, and IL-5 by ELISA assays; baseline expression of Jak-STAT signaling intermediates (Jak1, Tyk2, IFNAR, and IRF9) by immunoblot analysis; and interferon-stimulated gene expression by real time PCR and RT-PCR analysis.
After completion of study therapy, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Must have histologically or cytologically confirmed clear cell renal cell carcinoma (RCC)
- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension and is ≥ 1.0 cm by spiral CT scan
- No prior treatment except
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy > 6 months
- Good/intermediate Motzer prognostic status
- ANC ≥ 1,000/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10.0 g/dL
- Total bilirubin ≤ 2.0 mg/dL
- AST and ALT < 2.5 times normal
- Creatinine ≤ 1.8 mg/dL OR creatinine clearance > 50 mL/min
- Calcium < 12 mg/dL (when corrected for serum albumin)
- INR < 1.5 times upper limit of normal
- Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% by 2D echo
- Pulse oximetry ≥ 90% at rest on room air
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No evidence of bleeding diathesis
- No uncontrolled coagulation disorders
- No active infections requiring IV antibiotics
- No known HIV, hepatitis C, or hepatitis B
- No autoimmune disease requiring ongoing therapy
- No requirement for adrenal replacement
- No angina (controlled or uncontrolled)
- No uncontrolled hypertension
No history of other major medical illnesses including, but not limited to, any of the following:
- Cardiac ischemia
- Myocardial infarction
- Major cardiac arrhythmias
- Inflammatory bowel disorders
- No other prior malignancy except for previously treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 3 years
- No significant psychiatric disease that, in the opinion of the principal investigator, would preclude giving adequate informed consent or render immunotherapy unsafe
PRIOR CONCURRENT THERAPY:
No prior treatment for RCC except sunitinib malate
- Patients may have progressed or have been intolerant to sunitinib malate
- No prior systemic treatment for metastatic disease (other than sunitinib malate)
- No prior organ allografts
- At least 2 weeks since prior laparoscopic/robotic surgery
- At least 4 weeks since prior open nephrectomy
- More than 4 weeks since prior and no concurrent radiotherapy or other surgery
- More than 4 weeks since prior systemic steroids
- More than 2 weeks since prior topical, injected, or inhaled steroids
- No concurrent steroid therapy
- No concurrent Hypericum perforatum (St. John's wort)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Peginterferon alfa-2b
Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy.
This will most likely be a Monday or a Tuesday.
Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
|
Andra namn:
administered SC on day 1 of each week of therapy.
This will most likely be a Monday or a Tuesday.
Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Maximum Tolerated Dose of PEG-interferon Alfa-2b and Sorafenib Tosylate
Tidsram: up to 2 months
|
up to 2 months
|
Characterize the Toxicity of Peginterferon Alfa-2b and Sorafenib in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma.
Tidsram: up to 2 months
|
up to 2 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Progression-free Survival of Patients Receiving Peginterferon Alfa-2b and Sorafenib.
Tidsram: up to 1 year
|
up to 1 year
|
Response Rate of Patients Receiving Peginterferon Alfa-2b and Sorafenib.
Tidsram: up to 1 year
|
up to 1 year
|
Overall Survival
Tidsram: up to 1 year
|
up to 1 year
|
Activation of Interferon-induced Transcription Factors in Immune Cell Subsets by Flow Cytometry and Correlation of This Information With Clinical Outcome
Tidsram: up to 1 year
|
up to 1 year
|
Circulating Levels of IFN-γ and IL-5 for Determination of Th1/Th2 Status and CD4+, CD25+, and FoxP3 Cell Number (T Regs) in Peripheral Blood
Tidsram: Up to 1 year
|
Up to 1 year
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Thomas E. Olencki, DO, Ohio State University Comprehensive Cancer Center
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Urologiska neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Njursjukdomar
- Urologiska sjukdomar
- Adenocarcinom
- Carcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i njurarna
- Karcinom, njurcell
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antineoplastiska medel
- Immunologiska faktorer
- Proteinkinashämmare
- Interferoner
- Interferon-alfa
- Sorafenib
- Interferon alfa-2
- Peginterferon alfa-2b
Andra studie-ID-nummer
- OSU-06113
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Njurcancer
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Medical University of ViennaAvslutadSekundär hyperparatyreos | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NjurersättningÖsterrike
-
Hans BahlmannLinkoeping UniversityRekryteringNjurcancer | Uretercancer | Andra specificerade störningar av njure och urinledare | Benign Neoplasm av Ureter | Calculus of Kidney and Ureter | Ureterisk reflux | Medfödd ureteranomali | Benign renal neoplasmSverige
Kliniska prövningar på analys av genuttryck
-
Pusan National University HospitalAvslutad
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Philips Consumer LifestyleAvslutad
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
Kessler FoundationHar inte rekryterat ännu
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Candela CorporationRekryteringMeibomisk körteldysfunktion | Torra ögonsjukdomFörenta staterna, Argentina
-
Kessler FoundationRekryteringAutismFörenta staterna
-
Claret MedicalMeditrial Europe Ltd.Avslutad